tetano
Editor, Senior Moderator
J Virol. 2012 Oct 17. [Epub ahead of print]
Recombinant Parainfluenza Virus 5 Expressing HA Of Influenza A Virus H5N1 Protected Mice Against Lethal High Pathogenic Avian Influenza H5N1 Challenge.
Li Z, Mooney A, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B.
Source
Department of Infectious Diseases, University of Georgia, College of Veterinary Medicine, Athens, GA 30622.
Abstract
A safe and effective vaccine is the best way to prevent large-scale high pathogenic avian influenza virus (HPAI) H5N1 outbreaks in the human population. Currently FDA-approved H5N1 vaccine has serious limitations. A more efficacious H5N1 vaccine is urgently needed. Parainfluenza virus 5 (PIV5), a paramyxovirus, is not known to cause any illness in humans. PIV5 is an attractive vaccine vector. In our studies, a single dose of a live recombinant PIV5 expressing a HA gene of H5N1 (rPIV5-H5) from the H5N1 subtype provided sterilizing immunity against lethal dose of HPAI H5N1 infection in mice. Furthermore, we have examined the effect of insertion of H5N1 HA at different locations within the PIV5 genome on efficacy of PIV5-based vaccine. Interestingly, insertion of H5N1 HA between the leader sequence, the de facto promoter of PIV5, and the first viral gene, NP, did not lead to a viable virus. Insertion of H5N1 HA between NP and the next gene V/P led to a virus that was defective in growth. We have found that insertion of H5N1 HA at the junction between the SH gene and the HN gene gave the best immunity against HPAI H5N1 challenge: a dose as low as 1000 plaque forming unit (PFU) was sufficient to protect against lethal HPAI H5N1 challenge in mice. The work suggests that recombinant PIV5 expressing H5N1 HA has great potential as HPAI H5N1 vaccine.
PMID:
23077314
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23077314
Recombinant Parainfluenza Virus 5 Expressing HA Of Influenza A Virus H5N1 Protected Mice Against Lethal High Pathogenic Avian Influenza H5N1 Challenge.
Li Z, Mooney A, Gabbard JD, Gao X, Xu P, Place RJ, Hogan RJ, Tompkins SM, He B.
Source
Department of Infectious Diseases, University of Georgia, College of Veterinary Medicine, Athens, GA 30622.
Abstract
A safe and effective vaccine is the best way to prevent large-scale high pathogenic avian influenza virus (HPAI) H5N1 outbreaks in the human population. Currently FDA-approved H5N1 vaccine has serious limitations. A more efficacious H5N1 vaccine is urgently needed. Parainfluenza virus 5 (PIV5), a paramyxovirus, is not known to cause any illness in humans. PIV5 is an attractive vaccine vector. In our studies, a single dose of a live recombinant PIV5 expressing a HA gene of H5N1 (rPIV5-H5) from the H5N1 subtype provided sterilizing immunity against lethal dose of HPAI H5N1 infection in mice. Furthermore, we have examined the effect of insertion of H5N1 HA at different locations within the PIV5 genome on efficacy of PIV5-based vaccine. Interestingly, insertion of H5N1 HA between the leader sequence, the de facto promoter of PIV5, and the first viral gene, NP, did not lead to a viable virus. Insertion of H5N1 HA between NP and the next gene V/P led to a virus that was defective in growth. We have found that insertion of H5N1 HA at the junction between the SH gene and the HN gene gave the best immunity against HPAI H5N1 challenge: a dose as low as 1000 plaque forming unit (PFU) was sufficient to protect against lethal HPAI H5N1 challenge in mice. The work suggests that recombinant PIV5 expressing H5N1 HA has great potential as HPAI H5N1 vaccine.
PMID:
23077314
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23077314